CN Patent

CN1011118B — 治疗白内障的眼药水的制药方法

Assigned to HOSPITAL ATTACHED TO TIANJIN ACADEMY OF MEDICAL SCIENCES · Expires 1991-01-09 · 35y expired

What this patent protects

本发明属于医学药品及制造技术领域，为治疗白内障提供一种有实际临床疗效的眼药水及其制备方法。本发明眼药水的主要成分是L-3，5，3′-三碘甲状腺氨酸和L-3，5，3′，5′-四碘甲状腺氨酸。供滴眼或球结膜下注射用。至今未见明显副作用。对老年性皮质性白内障能减轻体征，稳定或提高视功能，对重症也有疗效，长期用药长期疗效好。除囊下性外，对其他白内障也有疗效。

USPTO Abstract

本发明属于医学药品及制造技术领域，为治疗白内障提供一种有实际临床疗效的眼药水及其制备方法。本发明眼药水的主要成分是L-3，5，3′-三碘甲状腺氨酸和L-3，5，3′，5′-四碘甲状腺氨酸。供滴眼或球结膜下注射用。至今未见明显副作用。对老年性皮质性白内障能减轻体征，稳定或提高视功能，对重症也有疗效，长期用药长期疗效好。除囊下性外，对其他白内障也有疗效。

Drugs covered by this patent

Unithroid (LEVOTHYROXINE SODIUM) · Fresenius Kabi

Patent Metadata

Patent number: CN1011118B
Jurisdiction: CN
Classification: —
Expires: 1991-01-09
Drug substance claim: No
Drug product claim: No
Assignee: HOSPITAL ATTACHED TO TIANJIN ACADEMY OF MEDICAL SCIENCES
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.